story of the week
Adjuvant Sorafenib for RCC at Intermediate or High Risk of Relapse
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology